Vectibix — Total revenues
Amgen Vectibix — Total revenues decreased by 96.7% to $287M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 96.5%, from $8.15B to $287M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market demand, successful clinical adoption, or effective pricing strategies for the oncology product, while a decrease may signal increased competition, patent expiration, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total gross sales generated from the global commercialization of a specific oncology therapeu...
Peer comparison
Comparable to oncology product revenue lines at other large-cap biotechnology or pharmaceutical firms, often benchmarked against market share in specific therapeutic areas.
amgn_segment_vectibix_total_revenuesHistorical Data
| Q2 '21 | Q2 '21 | Q3 '21 | Q3 '21 | Q4 '21 | Q4 '21 | Q1 '22 | Q1 '22 | Q2 '22 | Q2 '22 | Q3 '22 | Q3 '22 | Q4 '22 | Q4 '22 | Q1 '23 | Q1 '23 | Q2 '23 | Q2 '23 | Q3 '23 | Q3 '23 | Q4 '23 | Q4 '23 | Q1 '24 | Q1 '24 | Q2 '24 | Q2 '24 | Q3 '24 | Q3 '24 | Q4 '24 | Q4 '24 | Q1 '25 | Q1 '25 | Q2 '25 | Q2 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q4 '25 | Q1 '26 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.53B | $218.25M | $6.71B | $218.25M | $6.85B | $218.25M | $6.24B | $223.25M | $6.59B | $223.25M | $6.65B | $223.25M | $6.84B | $223.25M | $6.11B | $233M | $6.99B | $248M | $6.9B | $252M | $8.2B | $251M | $7.45B | $247M | $8.39B | $270M | $8.5B | $282M | $9.09B | $246M | $8.15B | $267M | $9.18B | $305M | $9.56B | $284M | $9.87B | $319M | $8.62B | $287M |
| QoQ Change | — | -96.7% | >999% | -96.7% | >999% | -96.8% | >999% | -96.4% | >999% | -96.6% | >999% | -96.6% | >999% | -96.7% | >999% | -96.2% | >999% | -96.5% | >999% | -96.3% | >999% | -96.9% | >999% | -96.7% | >999% | -96.8% | >999% | -96.7% | >999% | -97.3% | >999% | -96.7% | >999% | -96.7% | >999% | -97.0% | >999% | -96.8% | >999% | -96.7% |
| YoY Change | — | — | — | — | — | — | — | — | +1.0% | -96.6% | -0.8% | -96.7% | -0.1% | -96.7% | -2.1% | -96.3% | +5.9% | -96.2% | +3.8% | -96.2% | +19.8% | -96.3% | +22.0% | -96.0% | +20.1% | -96.1% | +23.2% | -95.9% | +10.9% | -97.0% | +9.4% | -96.4% | +9.4% | -96.4% | +12.4% | -96.7% | +8.6% | -96.5% | +5.8% | -96.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's vectibix — total revenues?
- Amgen (AMGN) reported vectibix — total revenues of $287M in Q1 2026.
- How has Amgen's vectibix — total revenues changed year-over-year?
- Amgen's vectibix — total revenues decreased by 96.5% year-over-year, from $8.15B to $287M.
- What does vectibix — total revenues mean?
- The total revenue generated from the sales of the Vectibix oncology therapeutic product.